ESR1 and hypertensive disorder: The estrogen receptor downregulator fulvestrant has been associated with less risk of cardiotoxicity, but some possible risk of hypertension [56] and ovarian function suppression, e.g. with triptorelin, has also been associated with risk of hypertension [56].